Selected research
Industry Research
Preformulation CDMO Service Industry Research Report 2026
Market perspective
The global Preformulation CDMO Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Preformulation CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Preformulation CDMO Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Preformulation CDMO Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Preformulation CDMO Service include Aenova, Ascendia Pharmaceutical, Aurigene Pharmaceutical Services, Corealis Pharma, CritiTech, Crystal Pharmatech, DPT Laboratories, Eirgen Pharma and Eurofins Scientific, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Preformulation CDMO Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Preformulation CDMO Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Preformulation CDMO Service Market by Company
Aenova
Ascendia Pharmaceutical
Aurigene Pharmaceutical Services
Corealis Pharma
CritiTech
Crystal Pharmatech
DPT Laboratories
Eirgen Pharma
Eurofins Scientific
Koziatek Consulting
Lonza
Oakwood Labs
Quotient Sciences
Sofpromed
Upperton Pharma Solutions
American Pharmaceutical Review
Bluepharma
Preformulation CDMO Service Segment by Type
Basic Characteristics CDMO Service
Pre-formulation Research CDMO Service
Prototype Formulation Development CDMO Service
Preformulation CDMO Service Segment by Application
Innovative Drug Development
Improved New Drug Development
Generic and Biosimilar Drug Development
Others
Preformulation CDMO Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preformulation CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Preformulation CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preformulation CDMO Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Preformulation CDMO Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Basic Characteristics CDMO Service
- Pre-formulation Research CDMO Service
- Prototype Formulation Development CDMO Service
Applications
- Innovative Drug Development
- Improved New Drug Development
- Generic and Biosimilar Drug Development
- Others
Companies covered
- Aenova
- Ascendia Pharmaceutical
- Aurigene Pharmaceutical Services
- Corealis Pharma
- CritiTech
- Crystal Pharmatech
- DPT Laboratories
- Eirgen Pharma
- Eurofins Scientific
- Koziatek Consulting
- Lonza
- Oakwood Labs
- Quotient Sciences
- Sofpromed
- Upperton Pharma Solutions
- American Pharmaceutical Review
- Bluepharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Preformulation CDMO Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Basic Characteristics CDMO Service
- 2.2.3 Pre-formulation Research CDMO Service
- 2.2.4 Prototype Formulation Development CDMO Service
- 2.3 Preformulation CDMO Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Innovative Drug Development
- 2.3.3 Improved New Drug Development
- 2.3.4 Generic and Biosimilar Drug Development
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Preformulation CDMO Service Breakdown Data by Type
- 3.1 Global Preformulation CDMO Service Historic Market Size by Type (2021-2026)
- 3.2 Global Preformulation CDMO Service Forecasted Market Size by Type (2027-2032)
4 Preformulation CDMO Service Breakdown Data by Application
- 4.1 Global Preformulation CDMO Service Historic Market Size by Application (2021-2026)
- 4.2 Global Preformulation CDMO Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Preformulation CDMO Service Market Perspective (2021-2032)
- 5.2 Global Preformulation CDMO Service Growth Trends by Region
- 5.2.1 Global Preformulation CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Preformulation CDMO Service Historic Market Size by Region (2021-2026)
- 5.2.3 Preformulation CDMO Service Forecasted Market Size by Region (2027-2032)
- 5.3 Preformulation CDMO Service Market Dynamics
- 5.3.1 Preformulation CDMO Service Industry Trends
- 5.3.2 Preformulation CDMO Service Market Drivers
- 5.3.3 Preformulation CDMO Service Market Challenges
- 5.3.4 Preformulation CDMO Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Preformulation CDMO Service Players by Revenue
- 6.1.1 Global Top Preformulation CDMO Service Players by Revenue (2021-2026)
- 6.1.2 Global Preformulation CDMO Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Preformulation CDMO Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Preformulation CDMO Service Head Office and Area Served
- 6.4 Global Preformulation CDMO Service Players, Product Type & Application
- 6.5 Global Preformulation CDMO Service Manufacturers Established Date
- 6.6 Global Preformulation CDMO Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Preformulation CDMO Service Market Size (2021-2032)
- 7.2 North America Preformulation CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Preformulation CDMO Service Market Size by Country (2021-2026)
- 7.4 North America Preformulation CDMO Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Preformulation CDMO Service Market Size (2021-2032)
- 8.2 Europe Preformulation CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Preformulation CDMO Service Market Size by Country (2021-2026)
- 8.4 Europe Preformulation CDMO Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Preformulation CDMO Service Market Size (2021-2032)
- 9.2 Asia-Pacific Preformulation CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Preformulation CDMO Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Preformulation CDMO Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Preformulation CDMO Service Market Size (2021-2032)
- 10.2 South America Preformulation CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Preformulation CDMO Service Market Size by Country (2021-2026)
- 10.4 South America Preformulation CDMO Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Preformulation CDMO Service Market Size (2021-2032)
- 11.2 Middle East & Africa Preformulation CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Preformulation CDMO Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Preformulation CDMO Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Aenova
- 12.1.1 Aenova Company Information
- 12.1.2 Aenova Business Overview
- 12.1.3 Aenova Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.1.4 Aenova Preformulation CDMO Service Product Portfolio
- 12.1.5 Aenova Recent Developments
- 12.2 Ascendia Pharmaceutical
- 12.2.1 Ascendia Pharmaceutical Company Information
- 12.2.2 Ascendia Pharmaceutical Business Overview
- 12.2.3 Ascendia Pharmaceutical Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.2.4 Ascendia Pharmaceutical Preformulation CDMO Service Product Portfolio
- 12.2.5 Ascendia Pharmaceutical Recent Developments
- 12.3 Aurigene Pharmaceutical Services
- 12.3.1 Aurigene Pharmaceutical Services Company Information
- 12.3.2 Aurigene Pharmaceutical Services Business Overview
- 12.3.3 Aurigene Pharmaceutical Services Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.3.4 Aurigene Pharmaceutical Services Preformulation CDMO Service Product Portfolio
- 12.3.5 Aurigene Pharmaceutical Services Recent Developments
- 12.4 Corealis Pharma
- 12.4.1 Corealis Pharma Company Information
- 12.4.2 Corealis Pharma Business Overview
- 12.4.3 Corealis Pharma Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.4.4 Corealis Pharma Preformulation CDMO Service Product Portfolio
- 12.4.5 Corealis Pharma Recent Developments
- 12.5 CritiTech
- 12.5.1 CritiTech Company Information
- 12.5.2 CritiTech Business Overview
- 12.5.3 CritiTech Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.5.4 CritiTech Preformulation CDMO Service Product Portfolio
- 12.5.5 CritiTech Recent Developments
- 12.6 Crystal Pharmatech
- 12.6.1 Crystal Pharmatech Company Information
- 12.6.2 Crystal Pharmatech Business Overview
- 12.6.3 Crystal Pharmatech Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.6.4 Crystal Pharmatech Preformulation CDMO Service Product Portfolio
- 12.6.5 Crystal Pharmatech Recent Developments
- 12.7 DPT Laboratories
- 12.7.1 DPT Laboratories Company Information
- 12.7.2 DPT Laboratories Business Overview
- 12.7.3 DPT Laboratories Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.7.4 DPT Laboratories Preformulation CDMO Service Product Portfolio
- 12.7.5 DPT Laboratories Recent Developments
- 12.8 Eirgen Pharma
- 12.8.1 Eirgen Pharma Company Information
- 12.8.2 Eirgen Pharma Business Overview
- 12.8.3 Eirgen Pharma Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.8.4 Eirgen Pharma Preformulation CDMO Service Product Portfolio
- 12.8.5 Eirgen Pharma Recent Developments
- 12.9 Eurofins Scientific
- 12.9.1 Eurofins Scientific Company Information
- 12.9.2 Eurofins Scientific Business Overview
- 12.9.3 Eurofins Scientific Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.9.4 Eurofins Scientific Preformulation CDMO Service Product Portfolio
- 12.9.5 Eurofins Scientific Recent Developments
- 12.10 Koziatek Consulting
- 12.10.1 Koziatek Consulting Company Information
- 12.10.2 Koziatek Consulting Business Overview
- 12.10.3 Koziatek Consulting Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.10.4 Koziatek Consulting Preformulation CDMO Service Product Portfolio
- 12.10.5 Koziatek Consulting Recent Developments
- 12.11 Lonza
- 12.11.1 Lonza Company Information
- 12.11.2 Lonza Business Overview
- 12.11.3 Lonza Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.11.4 Lonza Preformulation CDMO Service Product Portfolio
- 12.11.5 Lonza Recent Developments
- 12.12 Oakwood Labs
- 12.12.1 Oakwood Labs Company Information
- 12.12.2 Oakwood Labs Business Overview
- 12.12.3 Oakwood Labs Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.12.4 Oakwood Labs Preformulation CDMO Service Product Portfolio
- 12.12.5 Oakwood Labs Recent Developments
- 12.13 Quotient Sciences
- 12.13.1 Quotient Sciences Company Information
- 12.13.2 Quotient Sciences Business Overview
- 12.13.3 Quotient Sciences Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.13.4 Quotient Sciences Preformulation CDMO Service Product Portfolio
- 12.13.5 Quotient Sciences Recent Developments
- 12.14 Sofpromed
- 12.14.1 Sofpromed Company Information
- 12.14.2 Sofpromed Business Overview
- 12.14.3 Sofpromed Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.14.4 Sofpromed Preformulation CDMO Service Product Portfolio
- 12.14.5 Sofpromed Recent Developments
- 12.15 Upperton Pharma Solutions
- 12.15.1 Upperton Pharma Solutions Company Information
- 12.15.2 Upperton Pharma Solutions Business Overview
- 12.15.3 Upperton Pharma Solutions Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.15.4 Upperton Pharma Solutions Preformulation CDMO Service Product Portfolio
- 12.15.5 Upperton Pharma Solutions Recent Developments
- 12.16 American Pharmaceutical Review
- 12.16.1 American Pharmaceutical Review Company Information
- 12.16.2 American Pharmaceutical Review Business Overview
- 12.16.3 American Pharmaceutical Review Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.16.4 American Pharmaceutical Review Preformulation CDMO Service Product Portfolio
- 12.16.5 American Pharmaceutical Review Recent Developments
- 12.17 Bluepharma
- 12.17.1 Bluepharma Company Information
- 12.17.2 Bluepharma Business Overview
- 12.17.3 Bluepharma Revenue in Preformulation CDMO Service Business (2021-2026)
- 12.17.4 Bluepharma Preformulation CDMO Service Product Portfolio
- 12.17.5 Bluepharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst